Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas

Inclusion Criteria * Male or female patients aged 18 years or greater * Patients with confirmed diagnosis of NFPA evidenced by: magnetic resonance imaging (MRI) confirmation of pituitary adenoma and No pituitary tumoral hormone hypersecretion * Patients with no previous medical treatment * Patients who had been submitted to surgery but not cured. Lack of cure is defined as presence of remnant tumor on MRI at least three months after surgery (without any possible misinterpretation of postsurgical changes) * Patients with confirmed diagnosis of resistant prolactinoma by lack of prolactin normalization with a tolerated cabergoline dosage during 12 weeks * Patients who had been submitted to surgery due to resistance to cabergoline and not cured. Lack of cure is defined as lack of serum prolactin normalization or complete removal of tumor load * Patients who signed the informed consent Exclusion Criteria * Previous pituitary radiotherapy * High risk for transsphenoidal surgery * Patients with symptomatic cholelithiasis * Diabetic patients on antidiabetic medications those fasting blood glucose is poorly controlled as evidenced by HbA1C \> 8% * Patients with abnormal coagulation (prothrombin time (PT) or partial thromboplastin time (PTT) elevated by 30% above normal limits); * Patients receiving anticoagulants that affect PT or PTT * Patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, clinically significant brady…